Pharmaceutical revenue of Merck & Co by therapy class 2022

Merck and Co. generates the majority of its worldwide revenue from its pharmaceutical operating segment. Sales from the company’s oncology business, which focuses on drugs that treat cancer, accounted for the largest single share of its pharmaceutical revenue in 2022.

Revenues boosted by sales of cancer treatments

Merck & Co. is a global healthcare company that generated approximately 59.3 billion U.S. dollars in total revenue in 2022. The company has two reportable operating segments: pharmaceutical and animal health. The pharmaceutical segment is split into nine franchises - or therapeutic areas; oncology generated some 23 billion U.S. dollars in 2022 – a significant increase compared to the previous year. Sales of cancer drug Keytruda were particularly strong and increased from 7.17 billion in 2018 to 20.9 billion U.S. dollars in 2022.

An overview of Merck’s global operations

The corporate headquarters of Merck & Co. is located in New Jersey, and the company’s domestic market is the region that continues to generate the most of its revenue. Outside of the United States, Merck & Co. has operations in Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company’s sales in the Asia Pacific region showed some significant increase from 2021 to 2022. Operating business strategies in emerging markets, such as China, can come with challenges, but they offer huge potential for growth over time.